» Articles » PMID: 10644013

Expression of the MC1 Receptor Gene in Normal and Malignant Human Melanocytes. A Semiquantitative RT-PCR Study

Overview
Specialty Cell Biology
Date 2000 Jan 22
PMID 10644013
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Alpha melanocyte-stimulating hormone (MSH) and related proopiomelanocortin-derived (POMC) peptides bind to the melanocortin 1 receptor (MC1-R) of mammalian melanocytes and stimulate proliferation and melanogenesis. POMC transcripts and alpha-MSH-like immunoreactivity have been found in melanoma cells and a possible autocrine loop involving MC1-R and POMC-derived products has been proposed. Therefore, the alpha-MSH/MC1-R system plays a major role in the biology of melanocytes, and provides targets for melanoma diagnosis and therapy. However, the relative levels of MC1-R expression in normal melanocytes (NM) and melanoma cells are unknown, and it is still debated whether or not all human melanomas express the MC1-R. We describe a semiquantitative RT-PCR assay for MC1-R expression, using a competition vector generated by deleting 164 bp of the native gene. The competitor was employed to analyse a panel of human melanoma cells, tumour samples, giant congenital nevus cells (CNM) and normal melanocytes (NM). All samples were positive for MC1-R expression, but expression of the receptor gene did not correlate with that of tyrosinase. Expression levels were about 10 and 20 times higher for surgical specimens and cultured melanoma cells, respectively, than for NM, but comparable for CNM and NM. Thus, high MC1-R expression is a frequent event in malignant melanocytes, and might lead to a higher activity of the alpha-MSH/MC1-R system in melanoma cells as compared to normal melanocytes, for equal local concentrations of the hormone or related melanocortins.

Citing Articles

Extract Inhibits α-MSH-Induced Melanogenesis in B16F10 Cells via Down-Regulation of CREB Signaling Pathway.

Seo G, Ha Y, Park A, Kwon O, Kim Y Int J Mol Sci. 2019; 20(3).

PMID: 30695994 PMC: 6386916. DOI: 10.3390/ijms20030536.


Receptor-Mediated Melanoma Targeting with Radiolabeled α-Melanocyte-Stimulating Hormone: Relevance of the Net Charge of the Ligand.

Bapst J, Eberle A Front Endocrinol (Lausanne). 2017; 8:93.

PMID: 28491052 PMC: 5405074. DOI: 10.3389/fendo.2017.00093.


Malignant melanoma and melanocortin 1 receptor.

Rosenkranz A, Slastnikova T, Durymanov M, Sobolev A Biochemistry (Mosc). 2014; 78(11):1228-37.

PMID: 24460937 PMC: 4064721. DOI: 10.1134/S0006297913110035.


Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects.

Royalty J, Konradsen G, Eskerod O, Wulff B, Hansen B J Clin Pharmacol. 2013; 54(4):394-404.

PMID: 24166760 PMC: 4263154. DOI: 10.1002/jcph.211.


Multivalent Interactions: Synthesis and Evaluation of Melanotropin Multimers - Tools for Melanoma Targeting.

Brabez N, Saunders K, Nguyen K, Jayasundera T, Weber C, Lynch R ACS Med Chem Lett. 2013; 4(1):98-102.

PMID: 23524643 PMC: 3601667. DOI: 10.1021/ml300312b.